Kainic acid

产品说明书

Print
Chemical Structure| 487-79-6 同义名 : -
CAS号 : 487-79-6
货号 : A537335
分子式 : C10H15NO4
纯度 : 98%
分子量 : 213.23
MDL号 : MFCD00077806
存储条件:

Pure form Keep in dark place,Sealed in dry,2-8°C

In solvent -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 50 mg/mL(234.49 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 25 mg/mL(117.24 mM),配合低频超声,并水浴加热至45℃助溶

动物实验配方:
生物活性
描述 Kainic acid is a potent agonist at excitatory amino acid receptor subtypes in the CNS. Kainic acid is a potent neurotoxin, and induces selective neuronal loss in the rat hippocampus. Kainic acid acts on the kainate receptors, and kainic acid neurotoxicity may be in part mediated by oxidative stress[3]. The neurotoxic properties of kainic acid and ibotenic acid following intrahippocampal injection in neonatal rats and found significant pyramidal cell death following injection of 1.0 microgram kainic acid in 6, 7 and 9-day-old pups. At doses 2.5 or five times this amount, significant pyramidal cell loss was obtained in 5-day-old rats as well[4]. The systemic injection of a single low dose (7 mg/kg) of kainic acid to ovariectomized rats produced a marked loss of Nissl-stained and somatostatin-immunoreactive hilar neurons[5]. The kainic acid-induced lesions potentiated the locomotor response to both the dopaminergic agonist, d-amphetamine, and the cholinergic antagonist, scopolamine, attenuated the cataleptic response to the dopaminergic antagonist, haloperidol, and potentiated the cataleptic acid and convulsive responses to the cholinergic agonist, pilocarpine[6].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02108015 Healthy Volunteers Phase 1 Terminated - United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT03244345 Depression and Epilepsy Not Applicable Recruiting February 20, 2021 France ... 展开 >> Assistance Publique Hôpitaux de Marseille Recruiting Marseille, France, 13354 Contact: Aïleen Mc Gonigal, MD       aileen.mcgonigal@ap-hm.fr    Chu Tours Not yet recruiting Tours, France Contact: Bertrand DE TOFFOL, MD/PhD       bertrand.detoffol@univ-tours.fr 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

4.69mL

0.94mL

0.47mL

23.45mL

4.69mL

2.34mL

46.90mL

9.38mL

4.69mL

参考文献

[1]Riljak V, Marešova D, et al. Subconvulsive dose of kainic acid transiently increases the locomotor activity of adult Wistar rats. Physiol Res. 2015;64(2):263-7. Epub 2014 Oct 15.

[2]Levesque M, Avoli M. The kainic acid model of temporal lobe epilepsy. Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2887-99.

[3]Matsuoka Y, Kitamura Y, Okazaki M, Kakimura J, Tooyama I, Kimura H, Taniguchi T. Kainic acid induction of heme oxygenase in vivo and in vitro. Neuroscience. 1998 Aug;85(4):1223-33

[4]Cook TM, Crutcher KA. Intrahippocampal injection of kainic acid produces significant pyramidal cell loss in neonatal rats. Neuroscience. 1986 May;18(1):79-92

[5]Azcoitia I, Sierra A, Garcia-Segura LM. Estradiol prevents kainic acid-induced neuronal loss in the rat dentate gyrus. Neuroreport. 1998 Sep 14;9(13):3075-9

[6]Sanberg PR, Pisa M, Fibiger HC. Kainic acid injections in the striatum alter the cataleptic and locomotor effects of drugs influencing dopaminergic and cholinergic systems. Eur J Pharmacol. 1981 Sep 24;74(4):347-57

[7]Zheng Z, Liang P, Hou B, Lu X, Ma Q, Yu X, Han S, Peng B, Chen T, Liu W, Yin J, He X. The effect of dipeptidyl peptidase IV on disease-associated microglia phenotypic transformation in epilepsy. J Neuroinflammation. 2021 May 11;18(1):112.